HIF1A and B-cell chronic lymphocytic leukemia: Explicitly, targeting HIF-1α or its downstream regulatory pathways (e.g., CXCL12/CXCR4 axis) at the tumor and stromal cell levels may be a viable strategy to surmount HME-mediated protection of CLL cells.95